Our Financials & Outlook
The 2021 financial results are marked by unprecedented R&D progress and our successful Nasdaq listing.
Shareholder structure (January 2021)
Our capital strategy is a combination of non-dilutive funding sources and equity capital to finance the development of the Company’s vaccine candidates.
In 2022, Valneva expects to continue investing strongly in its R&D programs and increase vaccine sales, subject to regulatory approval of VLA2001.
Valneva’s financial reports
PETER BÜHLERChief Financial Officer